Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
- Conditions
- Bacteremia
- Registration Number
- NCT03148769
- Brief Summary
Bacteremia
The Hypothesis of the study are the followings:
* To demonstrate relevant epidemiologic and clinical changes with potentially impact in the management and prognosis of the patients with bacteremia.
* Since the diagnosis and management is heterogeneous between centers, we could identify a scenario to improve.
* To identify quality indicators in the management of bacteremia.
* To demonstrate that some interventions made by Bacteremia Team pose relevant impact in the prognosis of bacteremia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5320
- Every episode of bacteremia in patients older than 13 years old, confirmed microbiologically and clinically significant (presence of clinical sepsis data at diagnosis) should be prospectively included on the basis of standard criteria.
- Episodes of transient bacteremia may be included.
- Drugs will be prescribed in the usual way, according to the conditions established in the authorization. The assignment of a patient to a particular therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice, and the decision to prescribe a particular drug will be clearly dissociated from the decision to include to the patient in the study.
- Bacteremias without clinical relevance
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Epidemiology and prognostic factors of bacteremia episodes. From day 0 to day 30 * Global incidence and per type of acquisition.
* Global etiology and per type of acquisition.
* Frequency of multiresistant and emerging microorganism.
* Source of bacteremia.
* Clinical severity of presentation.
* Clinical failure, mortality at day 7, mortality at day 30, recurrence, length of stay and re-admission at hospital.
- Secondary Outcome Measures
Name Time Method Clinical management of patients with bacteremia during the episode. From day 0 to day 30 * Antibiotic therapy used during the episodes (empirical and targeted).
* Non antibiotic therapy/support therapy used during the episode.
* Frequency of focus search and adequate control.Differences in the management between types of services, wards and hospitals. From day 0 to day 30 Comparison between different services and hospital wards of variables regarding on the management of episodes.
Influence of clinical management in the prognosis. From day 0 to day 30 - Identifying prognostic factors related with mortality, clinical failure and recurrence.
Developing and validating a predictive model for early and late mortality. From day 0 to day 30 - Developing and validating a predictive model for mortality based in prognostic factors related with mortality.
Quality indicators in the management of bacteremia. From day 0 to day 30 - Identifying quality indicators in the management of episodes of bacteremia.
Interventions made by Bacteremia Team. From day 0 to day 30 * Frequency and type of interventions made by Bacteremia Teams.
* Impact of these interventions in the management and prognosis of episodes.
Trial Locations
- Locations (29)
Public Health Agency Business Hospital de Poniente.
🇪🇸El Ejido, Almería, Spain
General Hospital of Granollers
🇪🇸Granollers, Barcelona, Spain
University Hospital Mútua de Terrasa
🇪🇸Terrassa, Barcelona, Spain
Hospital Punta Europa
🇪🇸Algeciras, Cádiz, Spain
Jerez de la Frontera Hospital
🇪🇸Jerez de la Frontera, Cádiz, Spain
Hospital San Juan de la Cruz
🇪🇸Ubeda, Jaen, Spain
Hospital El Bierzo
🇪🇸Ponferrada, León, Spain
Costa del Sol Hospital
🇪🇸Márbella, Málaga, Spain
University Hospital of Vigo
🇪🇸Vigo, Pontevedra, Spain
University General Hospital of Alicante
🇪🇸Alicante, Spain
Scroll for more (19 remaining)Public Health Agency Business Hospital de Poniente.🇪🇸El Ejido, Almería, Spain